Nippon India Pharma Fund Direct-Growth
NAV
₹558.8780
as on 03 Jun 2025, 09:00 PM
₹-1.4584(0.26%)
Last Change
Scheme Information
Nippon India Pharma Fund Direct-Growth
as of 30 Apr 2025, 05:30 AM
₹8,259.60 Cr
0.89%
0.29%
Open-End
Growth
Exit load of 1% if redeemed within 1 month.
BSE Healthcare Total Return Index
View
Sectors Holding in this Mutual Fund
Healthcare
99.71%
₹8,235.65 Cr
Cash Holding
0.29%
₹23.95 Cr
Healthcare
99.71%
₹8,235.65 Cr
Cash Holding
0.29%
₹23.95 Cr
Sun Pharmaceutical Industries Ltd.
13.47%
₹1,112.57 Cr
Divi's Laboratories Ltd.
8.39%
₹692.98 Cr
Lupin Ltd.
7.67%
₹633.51 Cr
Cipla Ltd.
6.20%
₹512.10 Cr
Dr. Reddy's Laboratories Ltd.
6.05%
₹499.71 Cr
Others
58.22%
₹4,808.74 Cr
Sun Pharmaceutical Industries Ltd.
13.47%
₹1,112.57 Cr
Divi's Laboratories Ltd.
8.39%
₹692.98 Cr
Lupin Ltd.
7.67%
₹633.51 Cr
Cipla Ltd.
6.20%
₹512.10 Cr
Dr. Reddy's Laboratories Ltd.
6.05%
₹499.71 Cr
Others
58.22%
₹4,808.74 Cr
Funds in this Category
This fund's returns: 25.07%
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
Min. Investment
₹100
29.07
Category Returns
18.10%
29.07%
3Y Returns
29.07 %
SBI Healthcare Opportunities Fund Direct Plan-Growth
Min. Investment
₹500
28.23
Category Returns
18.10%
29.07%
3Y Returns
28.23 %
UTI Healthcare Fund Direct-Growth
Min. Investment
₹500
26.09
Category Returns
18.10%
29.07%
3Y Returns
26.09 %
About Nippon India Pharma Fund Direct-Growth
Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 17.28%, in last 3 years is 95.76% and 699.94% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
AUM: | ₹8,259.60 Cr |
Category: | Equity: Sectoral-Pharma |
Launch Date: | Invalid date |
Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
Address
Investment Performance
₹ 1,00,000
would have given a return of
₹1,10,871
₹1,21,647
₹1,90,567
₹1,95,758
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
Profit (absolute return)
₹95,758
95.76%
Investment Returns
Scheme Riskometer
Investors understand that their principal will be at very high risk